Apr 30 2021
ProductLife Group (PLG) has taken the next step in its evolution as a global leader in end-to-end regulatory compliance services. Just 6 months after the acquisition of the Vigilance and Medical Information group AxPharma, ProductLife Group has today announced the strategic acquisition of leading US regulatory drug development consultancy DSI. This allows PLG to expand in North America and reinforce its expertise to support clients in the regulatory development of their innovative therapies.
PLG is thus rolling out its strategic plan, defined one year ago with the arrival of Xavier Duburcq as CEO, with the ambition of becoming by 2023 the leading global provider of regulatory and compliance services for the life sciences industry.
ProductLife Group Enters US Market with Acquisition of Leading Regulatory Drug Development Consultancy DS InPharmatics (DSI)
Share Article
The strategic acquisition, which further strengthens PLG’s biopharma capability and provides a strong foothold in North America, is the next step in the Group’s global expansion plan
Together, PLG and DSI will be able to support clients in all stages of the product lifecycle, from pre-clinical work to post-approval compliance though the review and approval processes and market-entry strategy. This is a very exciting step for us all PARIS (PRWEB) April 28, 2021 ProductLife Group (PLG) has taken the next step in its evolution as a global leader in end-to-end regulatory compliance services. Just 6 months after the acquisition of the Vigilance and Medical Information group AxPharma, ProductLife Group has today announced the strategic acquisition of leading US regulatory drug